Singleron Biotechnologies is an innovative molecular diagnostic company dedicated to applying groundbreaking single cell analysis techniques in clinical diagnosis, drug development, and health management. The company was incorporated in January 2018 and currently has offices, laboratories, and manufacturing facilities in Nanjing and Suzhou in China, as well Connecticut， US； and Cologne, Germany.
Singleron has attracted a team of experts with diverse expertise since its incorporation. Currently, there are over 380 full-time employees in the company. The leadership team and key employees have long-year industry experience in multinational companies, including QIAGEN, Beckton Dickinson, Roche, Illumina, Siemens, TSMC, and Novogene. The technical team has extensive and diverse hands-on experience in single cell analysis, genomics, microfluidic systems, bioinformatics, database construction, instrument design, and clinical product development.
Singleron obtained a worldwide exclusive IP license from Yale University for its uniquely designed microfluidic single cell processing device, and has developed the GEXSCOPE® single cell system based on this microfluidic device. The GEXSCOPE® system offers a single cell analysis product format that is highly suitable for clinical applications by addressing typical challenges in single cell sequencing workflow, such as difficult sample transport, complicated procedure, and high cost. Since its incorporation, Singleron has quickly developed key proprietary technologies and methods on microfluidic system design, tissue processing, single cell barcoding and amplification, data analysis algorithms, data mining, and database construction, and applied for over twenty patents and has already been granted more than ten patents and over thirty software copyrights. GEXSCOPE® Single Cell RNA reagents and consumables, which enable RNA-seq library construction from thousands of single cells in parallel, were successfully launched in January 2019 and the Singleron Matrix instrument was launched in June 2020. The company has already worked with over 300 prominent research institutes, hospitals, and pharmaceutical companies, both in China and internationally, to promote adoption of innovative single cell analysis technologies in clinics and drug discovery.
•3000 m2 space for clinical lab, R&D lab, and office
•1200 m2 GMP manufacturing space
•Received Jiangbei Entrepreneurship and Nanjing Entrepreneurship awards
•1200 m2 lab and office space, GMP facility under construction
•Received BioBay Technology Leadership Award
•Labs and offices in Connecticut, US, and Cologne, Germany
•Technology development and global market development